NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on the topic.
- Other notable experts such as Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Naval G. Daver, MD, also contribute to the discussion.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Additional experts like Anne Chiang, MD, PhD, J. Douglas Miles, MD, PhD, FAAN, and Zev A. Shah, MD, FASCO, provide further perspectives.
Author's summary: NGS enhances biomarker testing in solid tumors.
More News
- Nigerian Govt Dismisses U.S. Claims of Religious Persecution
- Well-known figure in Delco veterans circles charged with carrying with a revoked permit
- 7 Standing Exercises That Slim Inner Thighs in 4 Weeks After 45 (No Gym Needed)
- Wanderers still chasing first win after Bulls draw
- Mega Millions jackpot reaches $800 million
- New Zealand complete 3-0 whitewash over England with thrilling two-wicket win in Wellington
- The power of organising and how to win the outsourcing battle | Article | News | UNISON National
- World Series: Yamamoto shines again, Dodgers force Game 7 thanks to game-ending double play
- Iran Unveils Christian-Themed Metro Station Amid Religious Persecution Controversy
- Barger: 'I was being too aggressive' on game-ending double play